Onyx Biotec IPO
IPO Listing Details
- Listing Date
22 Nov 2024
- Listing Price
₹ 54.05
- Listing Change
-11.39%
- Last Traded Price
₹ 67.80
IPO Details
- Open Date
13 Nov 2024
- Close Date
18 Nov 2024
- IPO Price Range
₹ 58 - ₹ 61
- IPO Size
₹ 29.34 Cr
- Listing Exchange
NSE SME
- Listing Date
21 Nov 2024
IPO Timeline
Onyx Biotec IPO Subscription Status
| Date | QIB | NII | Retail | TOTAL |
|---|---|---|---|---|
| 13-Nov-24 | 0.00 | 1.67 | 5.42 | 3.07 |
| 14-Nov-24 | 0.00 | 8.11 | 16.16 | 9.82 |
| 18-Nov-24 | 32.49 | 602.86 | 118.26 | 198.00 |
Last Updated: 18 November 2024 6:50 PM by 5Paisa
Onyx Biotec IPO is set to open on 13 November 2024 and will close on 18 November 2024. Onyx Biotec is a pharmaceutical company specialising in sterile water for injections and contract manufacturing.
The IPO is a fresh issue of 4.81 Cr shares aggregating to ₹29.34 Cr. The price range is set between ₹58 to ₹61 per share and the lot size is 2,000 shares.
The allotment is scheduled to be finalised on 19 November 2024. It will go public on NSE SME, with a tentative listing date of 21 November 2024.
Horizon Management is the book running lead manager while Mas Services Ltd is the registrar.
Onyx IPO Size
| Types | Size |
|---|---|
| Total IPO Size | ₹29.34 Cr |
| Offer For Sale | - |
| Fresh Issue | ₹29.34 Cr |
Onyx IPO Lot Size
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 1 | 2,000 | 1,22,000 |
| Retail (Max) | 1 | 2,000 | 1,22,000 |
| HNI (Min) | 2 | 4,000 | 2,44,000 |
Onyx Biotec IPO Reservation
| Investors Category | Subscription (times) | Shares Offered | Shares bid for | Total Amount (Cr.) |
|---|---|---|---|---|
| QIB | 32.49 | 9,12,000 | 2,96,34,000 | 180.77 |
| NII (HNI) | 602.86 | 6,88,000 | 41,47,68,000 | 2,530.08 |
| Retail | 118.26 | 16,00,000 | 18,92,10,000 | 1,154.18 |
| Total | 198.00 | 32,00,000 | 63,36,12,000 | 3,865.03 |
Onyx Biotec IPO Anchor Allocation
| Anchor Bid Date | 12 November, 2024 |
| Shares Offered | 1,366,000 |
| Anchor portion Size (In ₹ Cr.) | 8.33 |
| Anchor lock-in period end date for 50% shares (30 Days) | 19 December, 2024 |
| Anchor lock-in period end date for remaining shares (90 Days) | 12 February, 2025 |
1. Upgradation of existing manufacturing Unit I.
2. Setting up a high-speed cartooning packaging line at existing manufacturing Unit II.
3. Prepayment or repayment of all or a portion of certain loans.
4. General Corporate Purposes.
Onyx Biotec, established in May 2005, is a pharmaceutical company specialising in sterile water for injections and contract manufacturing. With a focus on quality and client satisfaction, Onyx Biotec offers a range of products, including Dry Powder Injections and Dry Syrups, for both domestic and international markets. Its two manufacturing units in Solan, Himachal Pradesh, have significant production capacities: Unit I produces 638,889 units of sterile water daily, while Unit II produces 40,000 units of dry powder injections and 26,667 units of dry syrup per day.
Onyx Biotec serves over 100 clients, including major names like Sun Pharma, Mankind, and Reliance Life Sciences. The company holds ISO 9001:2015 and ISO 14001:2015 certifications and employs 175 staff as of July 2024.
Peers
| Particulars (in Rs. Crores) | FY24 | FY23 | FY22 |
|---|---|---|---|
| Revenue | 53.87 | 39.62 | 44.98 |
| EBITDA | 8.41 | 4.59 | 5.76 |
| PAT | 3.03 | 1.84 | 3.35 |
| Particulars (in Rs. Crores) | FY24 | FY23 | FY22 |
|---|---|---|---|
| Total Assets | 74.14 | 58.72 | 36.84 |
| Share Capital | 13.32 | 5.90 | 5.90 |
| Total Borrowings | 30.78 | 29.23 | 12.24 |
| Particulars (in Rs. Crores) | FY24 | FY23 | FY22 |
|---|---|---|---|
| Net Cash Generated From / (used in) operating activities | 1.52 | 6.24 | 0.49 |
| Net Cash Generated From / (used in) investing activities | -3.15 | -22.67 | -5.78 |
| Net Cash Generated From / (used in) financing activities | 3.09 | 16.43 | 5.20 |
| Net Increase (Decrease) In Cash And Cash Equivalents | 1.46 | 0.00 | -0.09 |
Strengths
1. Established pharmaceutical company with extensive experience in sterile injections and contract manufacturing.
2. Strong client base with over 100 clients, including prominent pharmaceutical companies.
3. High production capacity with two specialised manufacturing units in Solan, Himachal Pradesh.
4. Certified with ISO 9001:2015 and ISO 14001:2015, ensuring quality and environmental standards.
5. Diverse product offerings for both domestic and international markets.
Risks
1. Heavy reliance on a limited range of products, especially sterile water for injections.
2. High dependence on a few major clients, which may affect revenue stability.
3. Regulatory changes in pharmaceutical standards could impact operations.
4. Operational risks tied to limited manufacturing locations, affecting scalability and expansion.
5. Competitive pressures in contract manufacturing may impact profit margins.
in 3
easy steps
Using 5paisa App or
Website
to block Payment
Open Free Demat Account
Be a part of 5paisa community - The first listed discount broker of India.
By proceeding, you agree to all T&C*
FAQs
Onyx Biotec IPO opens from 13 November to 18 November 2024.
The size of Onyx Biotec IPO is ₹29.34 Cr.
The price of Onyx Biotec IPO is fixed at ₹58 to ₹61 per share.
To apply for Onyx Biotec IPO, follow the steps given below:
● Login to your 5paisa account and select the issue in the current IPO section
● Enter the number of lots and the price at which you wish to apply for the Onyx Biotec IPO.
● Enter your UPI ID and click on submit. With this, your bid will be placed with the exchange.
You will receive a mandate notification to block funds in your UPI app.
The minimum lot size of Onyx Biotec IPO is 2,000 shares and the investment required is ₹1,16,000.
The share allotment date of Onyx Biotec IPO is 19 November 2024
The Onyx Biotec IPO will be listed on 21 November 2024.
Horizon Management Pvt Ltd is the book running lead manager for Onyx Biotec IPO.
Onyx Biotec plans to utilise the raised capital from the IPO for:
1. Upgradation of existing manufacturing Unit I.
2. Setting up a high-speed cartooning packaging line at existing manufacturing Unit II.
3. Prepayment or repayment of all or a portion of certain loans.
4. General Corporate Purposes.
Contact Information
Onyx Biotec
Onyx Biotec Limited
Bir Plassi Near Sainimajraropar,
Nalagarh Road
District Solan – 174101,
Phone: +91 172 265 6384
Email: generalinfo@onyxbiotec.com
Website: http://www.onyxbiotec.com/
Onyx Biotec IPO Register
Mas Services Limited
Phone: (011) 2610 4142
Email: ipo@masserv.com
Website: https://www.masserv.com/opt.asp
Onyx Biotec IPO Lead Manager
Horizon Management Private Limited
